A Phase 4 interventional study of Arvekap 0.1 mg (Triptorelin, Ipsen, France) and Ganirelix 0.25 (Orgalutran, Organon, The Netherlands) in Infertility, sponsored by Eugonia. Status unknown at 1 site in Greece. Open to female participants aged 21 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2006-12-29.
Sponsored by Eugonia · Phase 4, Interventional, and Treatment
The purpose of this study is to compare the efficacy of two controlled ovarian stimulation protocols, the GnRH agonist protocol, widely known as the "long" protocol, and the flexible GnRH antagonist protocol, in terms of pregnancy rates and embryological data, in infertile patients receiving IVF treatment.
The formulation of controlled ovarian stimulation protocols is one of the primary reasons for the successful development of IVF. The "long" GnRH agonist protocol, also known as the gold standard, has been widely used with considerable success. More recently, on the other hand, GnRH antagonist provide a new promising approach for endogenous gonadotrophin suppression by blocking the GnRH receptor. There is conflicting data in the literature regarding the relative merits of the two ovarian stimulation protocols.
COMPARISON: Pregnancy rates and embryological data will by assessed in IVF patients treated with either the "long" GnRH agonist (Arvekap) or the flexible GnRH antagonist (Ganirelix) protocol.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 300 is above the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Eugonia is the lead sponsor of 16 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Ongoing pregnancy per embryo transfer
Biochemical pregnancy per embryo transfer
Clinical pregnancy per embryo transfer
Embryological data
This study is status unknown, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eugonia